Pidilizumab

N/A

Report date: 2022/06/20 10:47:36

Base Information

Drug NamePidilizumab
Drug Alias NameCT-011MDV-9300
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaProstatic NeoplasmsOvarian Neoplasms +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaUnited StatesRomania +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCuretech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeth Israel Deaconess Medical CenterMedivation
Inactive CompaniesAugusta UniversityNational Institutes Of HealthCuretech Ltd +[8] 
Active IndicationsMultiple Myeloma
Inactive IndicationsPrimary mediastinal B cell lymphomaProstatic NeoplasmsOvarian Neoplasms +[15] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG